Organoidsciences Ltd. (KOSDAQ:476040)

Market Cap	212.04B
Revenue (ttm)	2.52B
Net Income (ttm)	-13.28B
Shares Out	6.55M
EPS (ttm)	-2,434.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,194
Average Volume	103,778
Open	32,050
Previous Close	32,200
Day's Range	31,300 - 32,350
52-Week Range	21,000 - 52,000
Beta	n/a
RSI	52.73
Earnings Date	n/a

About Organoidsciences

Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 476040

Financial Performance

In 2024, Organoidsciences's revenue was 1.95 billion, an increase of 22.77% compared to the previous year's 1.59 billion. Losses were -11.25 billion, -70.93% less than in 2023.